The American Society of Retinal Specialists Meeting was this past week in Boston. A poster was presented that compared the outcomes of 22 patients with bilateral macular holes. In one eye, they did a vitrectomy and membrane peel. In the other eye, an injection of Jetrea.
Quick recap: Jetrea (ocriplasmin) is an intravitreal injection that was FDA approved in 2012 for the treatment of symptomatic vitreomacular adhesion.
What did the study find?
They found that primary macular hole closure rates were higher in eyes that underwent a vitrectomy (91% vs. 36% with Jetrea). However, the final best corrected visual acuity was similar between the two eyes.